{"id":11588,"date":"2003-09-01T05:09:50","date_gmt":"2003-09-01T05:09:50","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=11588"},"modified":"2014-05-27T11:47:41","modified_gmt":"2014-05-27T11:47:41","slug":"t-20-launched-in-uk","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/11588","title":{"rendered":"T-20 launched in UK"},"content":{"rendered":"<p><strong>Following approval in the EU on 28 May, T-20 (enfuvirtide, Fuzeon), was launched in the UK on 3 July 2003.<\/strong><\/p>\n<p>It is the first of a new class of entry inhibitors, and results from studies in treatment experienced patients have been closely reported previously in HTB.<\/p>\n<p>Links:<\/p>\n<p>EMEA European Public Assessment Reports<br \/>\n<a href=\"http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/fuzeon\/fuzeon.htm\"> http:\/\/www.emea.eu.int\/humandocs\/Humans\/EPAR\/fuzeon\/fuzeon.htm<\/a><\/p>\n<p>Roche press release<br \/>\n<a href=\"http:\/\/www.roche.com\/med-corp-detail-2003?id=990&amp;media-language=e\"> http:\/\/www.roche.com\/med-corp-detail-2003?id=990&amp;media-language=e<\/a><\/p>\n<p>Enfuvirtide (T-20): predicting success and modelling survival benefits<br \/>\n<a href=\"http:\/\/www.i-base.info\/pub\/htb\/v4\/htb4-1\/Enfuvirtide.html\"> http:\/\/www.i-base.info\/pub\/htb\/v4\/htb4-1\/Enfuvirtide.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following approval in the EU on 28 May, T-20 (enfuvirtide, Fuzeon), was launched in the UK on 3 July 2003. It is the first of a new class of entry inhibitors, and results from studies in treatment experienced patients have &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-11588","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=11588"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/11588\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=11588"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=11588"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=11588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}